KMCRIC

Multiple clinical failures in the neurodegenerative field have sparked realisation that there is a critical need for discussion and debate between neurodegenerative drug developers to drive clinical success.

NDD Europe will overcome the translational challenges facing neurodegenerative drug developers by exploring the future biomarkers of neurodegeneration, improving preclinical modelling to increase clinical predictability and encouraging precompetitive strategies and collaboration amongst drug developers.

With 70+ thought-leaders converging at NDD Europe, this will be an unrivalled opportunity for you to gain the latest scientific insights, have your peers review your research and grow your collaborator network.